Products currently under clinical development  (as of August 1, 2014) Code No.  Generic Name Classification Target Disease Phase 1 Phase 2 Phase 3 Filed Area Dosage  Form Origin Remarks Urology YM905 solifenacin Muscarine M 3 receptor antagonist Neurogenic detrusor overac- tivity and idiopathic overactive  bladder in pediatric patients US/  Europe Oral In-house New  indication  (pediatric) EB178 solifenacin/mirabegron Concomitant use  of solifenacin and  mirabegron Urinary frequency, urinary  incontinence or urgency  associated with overactive  bladder US/  Europe/  Asia Oral In-house ASP3652 Inhibition of afferent  nerve activity Bladder pain syndrome/ Interstitial cystitis Europe Oral In-house Japan ASP4901 (AKP-002) PDE9 inhibitor Lower urinary tract symptoms  associated with benign  prostatic hyperplasia Japan Oral ASKA YM178 mirabegron Neurogenic detrusor overac- tivity and idiopathic overactive  bladder in pediatric patients Oral In-house New  indication  (pediatric) ASP5633 Stress urinary incontinence Oral In-house Immunology (including Transplantation) and Infectious Diseases ASP7374 Influenza vaccine Prophylaxis of seasonal  influenza Japan Injection UMN  Pharma * 1 (14/05) certolizumab pegol PEGylated anti-tumor necrosis  factor-alpha antibody Disease modifying anti-  rheumatic drugs (DMARD)- naïve rheumatoid arthritis Japan Injection UCB New  indication* 1 (14/06) isavuconazole Azole antifungal Invasive aspergillosis and  invasive mucormycosis US Injection Oral Basilea * 2 (14/07) Candidemia/Invasive  candidiasis US ASP0113 (VCL-CB01) DNA vaccine for  cytomegalovirus Cytomegalovirus reactivation  in hematopoietic cell transplant recipients US/ Europe/ Japan Injection Vical Cytomegalovirus infection  or reactivation in solid organ  transplant recipients US/  Europe fidaxomicin Macrocyclic  antibiotic Infectious enteritis (bacterial  target:  Clostridium difficile ) Japan Oral Cubist Clostridium difficile  infection in pediatric patients Europe Oral ASP015K JAK inhibitor Rheumatoid arthritis Japan Oral In-house US/ Europe* 3 ASKP1240 Anti-CD40 monoclonal  antibody Prevention of organ transplant rejection US Injection Kyowa  Hakko  Kirin Japan ASP7373 Influenza vaccine Prophylaxis of H5N1 influenza Japan Injection UMN  Pharma * 1 *1 Local development (Japan) *2 Local development (US) *3 A license agreement was executed with Janssen Biotech, Inc. for the development and commercialization worldwide except for Japan. Phase 2b studies were completed by Astellas. Astellas Pharma Inc.  _ Annual Report 2014 38